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Abstract 
BACKGROUND: Patients with hepatitis Be antigen-negative chronic hepatitis B (HBeAg-negative CHB), and 
patients' inactive carriers (IC) have similar laboratory and serologic characteristics and are not always easy to 
distinguish. 
AIM: To characterise hepatitis Be antigen (HBeAg) negative chronic hepatitis B cohort based on their laboratory 
and virology evaluations at one point of time.  
METHODS: A prospective non-randomized study was conducted on 109 patients with HBeAg negative chronic 
hepatitis B treated as outpatients at the Clinic for Infectious Diseases and Febrile Conditions. All patients 
underwent laboratory and serology testing, quantification of HBV DNA and HBs antigen (qHBsAg). 
RESULTS: A group of 56 patients were inactive carriers (IC), and 53 patients had HBeAg-negative CHB (AH). 
The mean values of ALT, HBV DNA and qHBsAg in IC were 29.13 U/L; 727.95 IU/ml and 2753.73 IU/ml 
respectively. In the AH group, the mean values of ALT, HBV DNA and quantitative HBsAg were 50.45 U/L; 
7237363.98 IU/ml and 12556.06 IU/ml respectively. The serum value of ALT was more influenced by qHBsAg 
than HBV DNA in both IC and AH groups (R = 0.22 vs R = 0.15) (p > 0.05). 
CONCLUSION: patients with inactive and active HBeAg-negative CHB have similar laboratory and serology 
profile. It is necessary to combine analysis of ALT, HBV DNA and qHBsAg for better discrimination between 
patient's IC and patient with HBeAg-negative CHB. 
 
 
 
 
 
 
 
 
 
Introduction 
 
Infection with hepatitis B virus (HBV) remains 
the leading cause of liver damage and represents one 
of the major health problems worldwide. Nowadays, it 
is considered that approximately 30% of the world 
population has serologic evidence of current or past 
infection with HBV
 
and 248 to 257 million people are 
chronic HBV carriers on a global level [1]. Chronic 
hepatitis B virus infection is associated with serious 
complications such as cirrhosis, hepatocellular 
carcinoma (HCC) end-stage liver disease and death 
[2], [3], [4]. The natural history of chronic hepatitis B 
(CHB) is characterised by different phases of 
infection, and patients may evolve from one phase to 
another or may revert to a previous phase and not 
necessarily in sequential order. The phases of the 
natural history of chronic HBV infection have been 
schematically divided into five phases, taking into 
account the presence of HBeAg, HBV DNA (hepatitis 
B virus deoxyribonucleic acid) levels, alanine 
transaminase (ALT) values and the presence or 
absence of liver inflammation [5]. The hepatitis B-e 
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antigen (HBeAg) positive phase is characterized by 
high serum HBV DNA levels, and HBeAg negative 
phase is characterised with HBeAg loss and 
seroconversion with the occurrence of anti HBe 
antibodies, which is usually associated with the 
decline of HBV DNA levels, and normalisation of ALT 
values [5], [6]. In some patients, this process of 
seroconversion to HBeAg negative phase is 
associated with the selection of HBV variants that 
express little or no HBeAg at all and is usually 
characterised with continuing HBV DNA replication 
and progression of liver damage [5], [6], [7]. Usually, 
most
 
of the chronically infected HBV patients 
experience the inactive phase with normal ALT levels, 
low viraemia and negative HBeAg after HBeAg 
seroconversion. However, up to 10-30% of chronic 
HBV infected adults subjects may suffer from HBeAg-
negative hepatitis flare after HBeAg seroconversion, 
especially in those who experience late HBeAg 
seroconversion, and are associated with increased 
life-long risk of liver cirrhosis and HCC [8], [9]. It has 
been estimated that the median prevalence of HBe 
antigen-negative chronic hepatitis B infection is 
around 33% in the Mediterranean, 15% in the Asia 
Pacific, and 14% in the USA and Northern Europe 
[10]. Patients with HBeAg-negative CHB represent a 
heterogeneous group characterised with a different 
range of viral replication and liver disease severity, 
seen by fluctuating levels of HBV DNA and 
transaminases with temporary remissions during the 
disease [11]. Therefore, it is necessary to make a 
distinction among those with active hepatic necrotic 
inflammation and persistent viraemia as they have 
higher rates of complications (patients with chronic 
HBeAg negative hepatitis B) in contrast to HBeAg-
negative CHB patients who are inactive carriers. Both 
forms of CHB, patients with HBeAg negative chronic 
hepatitis and patients' inactive carriers, have similar 
laboratory and serologic characteristics and are not 
always easy to distinguish [8]. In an inactive carrier, 
ALT usually remains normal on serial monitoring with 
undetectable to low levels (i.e., < 2000 IU/ml) of HBV 
DNA. However, the same may also occur in a patient 
with HBeAg-negative CHB. It is known that 
maintained high levels of HBV DNA are associated 
with progressive liver disease. Serum DNA levels are 
a prognostic factor, and contribute to defining the 
phases of CHB infection, the treatment indication, and 
allow an assessment of the efficacy of antiviral 
therapy [11], [12].  
Eradication of HBV should be useful both for 
the patients and the society. There are consensus 
guidelines that help the clinicians to make decisions 
about whether or not to treat a patient. The viral load 
cannot be considered as the only treatment criterion. 
HBV DNA persists even in persons who have 
serological recovery from acute HBV infection [13] 
Areas of uncertainty whether and when to treat 
patients with HBeAg negative chronic hepatitis still 
exist, and clinicians, patients, and public health 
authorities must, therefore, continue to make choices 
on the basis of the evolving evidence [11], [14], [15]. 
The identification of patients with chronic HBeAg 
negative infection (inactive carriers-IC) versus patients 
with chronic HBeAg-negative chronic hepatitis B (AH) 
is a complex issue due to the dynamic character of 
hepatitis B infection. Proper and timely assessment of 
patients with HBeAg negative chronic hepatitis B is 
important for early treatment decision and consecutive 
prevention of disease progression and development of 
chronic hepatitis B virus-associated complications. In 
this study, we evaluated the laboratory, serological 
and virological characteristics of an outpatient cohort 
of HBeAg negative chronic hepatitis B. 
 
 
Material and Methods 
 
A prospective non-randomized study was 
carried out on 109 patients with HBeAg negative CHB, 
treated at the Clinic for Infectious Diseases and 
Febrile Conditions in Skopje, the Republic of 
Macedonia from the period of November 2016 till 
January 2018. All patients who were HBsAg-positive 
for at least six months, but HBeAg-negative, anti-HBe-
positive, and had detectable HBV DNA in the serum 
were included in the study. Patients under the age of 
18 years, all patients who tested positive for hepatitis 
A, hepatitis C and HIV were not included in the study. 
Other excluding criteria were previous or current 
exposure to antiviral hepatitis B treatment, alcoholic 
and autoimmune liver diseases, incomplete serum 
profile and a follow-up period of fewer than six 
months. Patients with hepatocellular carcinoma 
(HCC), decompensated liver disease and pregnant 
patients were excluded from the study.  
The following data were obtained for all the 
patients: age, sex, alcohol consumption, complete 
blood count, bilirubin levels, transaminase, AFP, 
serology, quantification of HBV DNA, quantification of 
hepatitis B surface antigen (qHBsAg), abdominal 
ultrasound, total protein electrophoresis and presence 
of clinical signs and symptoms for cirrhosis. Cirrhosis 
was determined with the presence of ascites, 
encephalopathy, palmar erythema, telangiectasia, 
jaundice, hypoalbuminemia and ultrasound finding of 
cirrhosis. Complete serology profile was performed 
with ELISA (enzyme-linked immune assay) tests. The 
normal upper limit of serum transaminase both for 
alanine aminotransferase (ALT) and aspartate 
aminotransferase (ALT) was 40 U/L, according to the 
traditional cut-off values. Quantification of HBV DNA 
levels in the plasma was performed in-house, by real-
time polymerase chain reaction (RT-PCR) on COBAS 
AmpliPrep COBAS TaqMan HBV test and Abbott m 
2000 sp/m 2000 rt with a lower detection limit of 10 
IU/mL. The serum level of HBsAg (qHBsAg) was 
quantified with Architect HBsAg assay (Abbott 
Laboratories) in-house, according to the 
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manufacturers’ protocol. The detection level of HBsAg 
varies from 0.05 to 250 IU/ml. HBsAg levels above 
250 IU/ml were further diluted in a ratio of 1:500. 
We evaluated the serum values of alanine 
transaminase (ALT) aspartate transaminase (AST), 
qHBsAg and HBV DNA. A multiple regression 
analysis was performed to establish the correlation 
between the serum levels of ALT with qHBsAg and 
HBV DNA.  
Relevant clinical variables were gender, age, 
platelet count, ALT, AST, HBsAg, hepatitis B e 
antigen, HBV DNA. The value of ALT and AST are 
expressed in units per litre (U/L), and those of 
qHBsAg and HBV DNA were expressed in 
international units per millilitre (IU/ml). 
 
Adopted Definitions 
An inactive carrier was considered when 
HBeAg nonreactive with normal transaminase levels, 
HBV-DNA < 2000 IU/ml [11].  
Active chronic HBeAg negative hepatitis was 
considered when HBeAg nonreactive, and if ALT was 
elevated above the upper normal limit and HBV-DNA 
was more than 2,000UI/mL [11].  
The study was approved by the Ethics 
Committee of the Medical Faculty in Skopje. 
 
Statistical Analysis 
All data were processed using a statistical 
computer program Statistica 7.1 for Windows and 
SPSS Statistics 17.0. Series with attributive variables 
were analysed with percentages of structure. For 
numerical variables descriptive statistics ((Mean; Std. 
Deviation; ± 95.00% CI; Minimum; Maximum) was 
used, where frequencies and percentages were used 
for the description of the categorical variables. 
Distribution of the data was tested with Kolmogorov-
Smirnov tests; Lilliefors test; Shapiro-Wilks test(p). 
The differences between the groups were analysed 
with Pearson Chi-square (p) and Fisher’s exact test 
(p). T-test for independent variables (t/p) and Mann-
Whitney U test (Z/p) were used depending on the 
distribution of the data. Multiple Regression (R/p) was 
used to determine the correlation between ALT, 
qHBsAg and HBV DNA. For all analyses P values of 
<, 0.05 were considered significant.  
 
 
Results 
 
Out of 109 patients included in the study, 80 
(73.39 %) were male, and 29 (26.61%) were female. If 
in the analysis of the presentation forms at one point 
of time we considered only the baseline values of ALT 
and HBV DNA according to definitions used, 56 
patients (51.37%) had chronic hepatitis B infection, or 
as previously defined inactive carriers (IC), and 53 
(48.62%) had HBeAg-negative CHB (AH). In the 
group of inactive carries, the mean age of the patients 
was 37.50 ± 10.84 years, while in the group of AH 
was 43.91 ± 11.72 years. For Pearson Chi-square = 
0.002 and p > 0.05 (p = 0.97) there was no statistically 
significant difference between both groups of patients 
in terms of gender. Patients with AH for t = -2.96 and 
p < 0.01 (p = 0.004) were significantly older than 
patient's IC (Table 1) 
Table 1: Demographic and descriptive statistics in patients' 
inactive carriers and patients with HBeAg-negative chronic 
hepatitis B 
Characteristics n (%) 
IC 56 (51.37%) 
AH 53 (48.62%) 
Sex 
 
Male 80 (73.39 %) 
Female 29 (26,61%) 
Parameter Group N Mean Confidence 
-95,00% 
Confidence 
+95,00% 
Minimum Maximum Std.dev. 
Age 
(years)  
IC  56 37,50 34,60 40,40 19 67 10,84 
AH 53 43,91 40,67 47,14 22 74 11,72 
ALT U/L IC 56 29,13 24,43 33,82 10 89 17,53 
AST U/L 56 22,20 20,10 24,29 14 57 7,81 
ALT U/L AH 53 50,45 39,83 61,07 10 173 38,53 
AST U/L 53 34,74 29,37 40,10 12 101 19,46 
Abbreviations: IC-inactive carriers; AH- HBeAg-negative chronic hepatitis B; ALT-alanine 
transaminase; AST-aspartate transaminase. 
 
The mean value of ALT and AST in IC and 
AH patients was 29.13 ± 17.53 U/L; 22.20 ± 7.81 U/L; 
50.45 ± 38.53U/L and 37.74 ± 19.46 U/L, respectively 
(Table 1). When the levels of transaminases were 
compared, patients with AH had significantly higher 
ALT values compared to IC for Z = -3.18 and p > 0.01 
(p = 0.001), as well as for AST (Z = -4.06 и p < 0.001 
(p = 0.000)) (Table 2). 
Table 2: Differences in transaminases levels in patients' 
inactive carriers and patients with HBeAg-negative chronic 
hepatitis B 
Parameter 
Rank Sum 
IC 
Rank Sum 
AH 
U Z 
adjusted 
p-level N 
IC 
N 
AH 
ALT U/L 2556.50 3438.50 960.50 -3.18 0.001 56 53 
AST U/L 2410.50 3584.50 814.50 -4.06 0.000 56 53 
alkaline phosphatase 
U/L 
3028.00 2967.00 1432.00 -0.32 0.75 56 53 
Gamma GT U/L 2649.50 3345.50 1053.50 -2.61 0.009 56 53 
Abbreviations: IC-inactive carriers; AH- HBeAg-negative chronic hepatitis B; ALT-alanine 
transaminase; AST-aspartate transaminase; Gamma GT-Gamma-glutamyl transferase. 
 
The mean value of HBV DNA in IC and AH 
group were 727.95 ± 584.24 IU/ml and 7237363.98 ± 
46513427.91 IU/ml respectively. The mean value of 
quantitative HBsAg in IC was 2753.73 IU/ml and in the 
AH group 12556.06 ± 27188.85 IU/ml (Table 3).  
Table 3: Quantitative HBsAg and HBV DNA levels in patients' 
inactive carriers and patients with HBeAg-negative chronic 
hepatitis B 
 Parameter N Average Confi-dence 
-95,00% 
Confi-dence 
+95,00% 
Min Max Std.dev 
IC patients qHBsAg IU/ml 56 2753.73 1494.72 4012.74 0.05 19636.84 4701.29 
HBV DNA IU/ml 56 727.95 571.49 884.41 10 1997 584.24 
AH patients qHBsAg IU/ml 53 12556.06 5062 20050 12.95 155311.00 27188.85 
HBV DNA IU/ml 53 7237363.98 -5583325 20058053 2061 338999252 46513427.91 
Abbreviations: IC-inactive carriers; AH- HBeAg-negative chronic hepatitis B; HBV DNA- 
hepatitis B virus deoxyribonucleic acid; qHBsAg-quantitative hepatitis Bs antigen. 
 
Dimzova et al. Characteristics of an Outpatient Cohort with HBeAg-Negative Chronic Hepatitis B 
_______________________________________________________________________________________________________________________________ 
_______________________________________________________________________________________________________________________________ 
Open Access Maced J Med Sci. 2019 Jul 15; 7(13):2068-2074.                                                                                                                                                 2071 
 
In the group of patients IC, 29 (51.79%) had 
qHBsAg < 1000 IU/ml, and 27 (48.21%) had qHBsAg 
> 1000 IU/ml, while in the group of patients with active 
hepatitis (AH) 6 (11.32%) had qHBsAg < 1000 IU/ml, 
and 47 (88.68%) had qHBsAg > 1000 IU/ml. When the 
levels of HBV DNA in AH group were stratified, 27 
(50.94%) had HBV DNA > 2000 ≤ 20 000 IU/ml and 
26 (49.06%) had HBV DNA > 20000 IU/ml.  
Obviously, all patients' inactive carriers had 
HBV DNA level < 2000 IU/ml (Table 4). For Pearson 
Chi-square = 20,45 and p < 0.001 (p = 0.000) in the 
AH group of patients qHBsAg > 1000 IU/ml is 
significantly more represented. 
Table 4: Distribution of quantitative HBsAg and HBV DNA in 
patients' inactive carriers and patients with HBeAg-negative 
chronic hepatitis B 
IC AH 
qHBsAg No. Cumulative 
No. 
% Cumulative 
% 
qHBsAg No Cumulative 
No. 
% Cumulative 
% 
< 1000 
IU/ml 
29 29 51.79 51.79 < 1000 
IU/ml 
6 6 11.3
2 
11.32 
> 1000 
IU/ml 
27 56 48.21 100.00 > 1000 
IU/ml 
47 53 88.6
8 
100.00 
Missing 0 56 0,00 100.00 Missing 0 53 0.00 100.00 
HBV DNA  No. Cumulative 
No. 
% Cumulative 
% 
HBV 
DNA  
No. Cumulative 
No. 
% Cumulative 
% 
< 2000 
IU/ml 
56 56 100.00 100.00 ≥ 2000 - 
≤ 20000 
IU/ml 
27 27 50.9
4 
50.94 
> 20000 
IU/ml 
26 53 49.0
6 
100.00 
Missing 0 56 0.00 100.00 Missing 0 53 0.00 100.00 
Abbreviations: IC-inactive carriers; AH- HBeAg-negative chronic hepatitis B; HBV DNA- 
hepatitis B virus deoxyribonucleic acid; qHBsAg-quantitative hepatitis B s antigen. 
 
Patients with AH for Z = -5.10 and p < 0.001 
(p = 0.0000) had statistically significant higher values 
of qHBsAg compared to patients' inactive carriers. 
Likewise, for Z = -8.99 and p < 0.001 (p = 0.000) 
patients with active hepatitis have significantly higher 
values of quantitative HBV DNA than patient's IC 
(Table 5).  
Table 5: Differences between quantitative HBsAg and HBV 
DNA in patients' inactive carriers and patients with HBeAg-
negative chronic hepatitis B 
Parameter Rank Sum 
IC 
Rank Sum 
AH 
U Z 
adjusted 
p-level N 
IC 
N 
AH 
qHBsAg IU/ml 2238.00 3757.00 642.00 -5.10 0.000 56 53 
HBV DNA IU/ml 1596.00 4399.00 0.00 -8.99 0.000 56 53 
Abbreviations: IC-inactive carriers; AH- HBeAg-negative chronic hepatitis B; HBV DNA- 
hepatitis B virus deoxyribonucleic acid; qHBsAg-quantitative hepatitis Bs antigen. 
 
Individualized analysis of the serum profile 
and the measurements of HBV DNA/ALT/qHBs 
antigen showed that the increase of the level of HBV 
DNA is followed with a non-significant decrease of 
ALT, both in IC and in patients with AH, while the 
increase of the level of quantitative HBsAg is followed 
with the increase of the level of ALT in both groups of 
patients. The influence of qHBsAg is significantly 
stronger than that of HBV DNA.  
For each single increase of serum HBsAg, 
serum ALT increases for 0.0008 IU/ml p > 0.05 (p = 
0.11) in IC group of patients, while in AH group of 
patients, the serum level of ALT increases for 0.0002 
IU/ml p > 0.05 (p = 0.33) (Table 6). 
Table 6: Multiple regression analysis of ALT/HBV DNA/qHBsAg 
in patients' inactive carriers and patients with HBeAg- negative 
chronic hepatitis B 
IC AH 
 
Dependent Variable: ALT; R= 0.22; F(2.53)=1.39 and 
p<0.26 
 Beta Std.Err. 
of Beta 
B Std.Err. 
of B 
t(53) p-level 
Intercept   28.29 3.89 7.27 0.000 
qHBsAg 0.22 0.13 0.0008 0.0005 1.64 0.11 
HBV 
DNA 
-0.07 0.13 -0.002 0.004 -0.49 0.63 
 
Dependent Variable: ALT; R= 0.15; F(2.50)=0.59 and 
p<0.66 
 Beta Std.Err. 
of Beta 
B Std.Err. 
of B 
t(53) p-level 
Intercept   47.64 5.93 8.03 0.000 
qHBsAg 0.17 0.17 0.0002 0.000 0.99 0.33 
HBV 
DNA 
-0.04 0.17 -0.000 0.000 -0.22 0.83 
 
Abbreviations: IC-inactive carriers; AH- HBeAg-negative chronic hepatitis B; HBV DNA- 
hepatitis B virus deoxyribonucleic acid; qHBsAg-quantitative hepatitis Bs antigen. 
 
 
 
Discussion 
 
HBeAg negative, antique positive chronic 
hepatitis B is a capricious disease characterised with 
a dynamic and complex interaction between the virus, 
the hepatocytes and the host’s immune system [6], 
[7], [8], [16], [17]. The Republic of Macedonia has an 
estimated HBsAg prevalence around 1-4% [18] and 
having in mind that chronic HBV infection is the major 
pathogen causing chronic hepatitis, liver cirrhosis, and 
hepatocellular carcinoma (HCC) in the world, this 
imposes serious burden both on the individual and 
society as well [3], [5], [19]. It is very important to 
distinguish chronic inactive HBsAg carriers from 
HBeAg-negative CHB patients because the 
progression of the liver damage occurs primarily 
during the active hepatitis phase, and this group of 
patients has the potential of developing marked viral 
reactivation and has less chance of response to 
antiviral medications [20]. In the currently available 
guidelines, the recommendation is that HBV DNA, 
ALT, and HBeAg be analysed together and with great 
care for therapy decision making and the indication of 
the need for biopsy [11], [14], [15]. 
The results from the patients included in our 
study showed that there is no statistical significance 
between inactive carrier group and patients with 
HBeAg-negative CHB in terms of gender, although in 
the literature HBeAg-negative CHB is more expressed 
in males [21], [22], [23].
 
At the same time, the patients 
in our cohort with HBeAg-negative CHB are older than 
the patient's inactive carriers, which is consistent with 
the findings described in the literature [5], [23]. Chu et 
al., [24] followed 1.965 inactive HBV carriers' patients 
during 11.5 years and found out that 314 patients had 
reactivation of HBV. The risk for reactivation had a 
positive correlation with older age (p < 0.0001) and 
male sex (p < 0.0001). At the same time, the risk for 
developing cirrhosis also had a statistically significant 
correlation with advanced age and HBV reactivation 
(p = 0.004) and (p < 0.0001), respectively. The study 
showed that male sex (p = 0.037) and advanced age 
(p = 0.006) were two independent factors for HBV 
reactivation. The REVEAL-B study carried out by 
Chen et al., [23],
 
besides HBeAg positivity and high 
HBV viraemia identifies male gender, older patients, 
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alcoholism and high BMI (body mass index), as 
factors associated with HBV disease progression 
similar to the findings of Fattovich et al., [5].
 
Alanine transaminase (ALT) levels have 
traditionally been used for treatment decisions in 
chronic hepatitis B virus-infected patients. In the study 
of Ijaz et al., [25] 567 patients with HBeAg negative 
CHB were investigated, and 228 were classified as 
chronic inactive carriers, and 339 with chronic active 
hepatitis B. The serum enzyme levels of ALT, AST 
showed significant and high AUROC in differentiation 
between HBeAg negative IC and HBeAg negative 
patients with chronic hepatitis. The AUROC for ALT 
and AST was 0.997 and 0.969, respectively. Similar to 
Ijaz’s study, when the levels of transaminases were 
compared in our cohort, patients with HBeAg-negative 
CHB had significantly higher ALT and AST values 
compared to IC patients. The serum level of ALT is a 
factor to consider in the treatment of CHB patients, 
and a high ALT level helps to distinguish between the 
inactive carrier state and asymptomatic HBeAg-
negative CHB patients with normal ALT [26]. The 
findings of low serum levels of transaminases in the 
patients inactive carriers included in our study is 
compatible with the observation that low and normal 
levels are expected in both patients inactive carriers 
and patient with HBeAg negative chronic hepatitis B, 
[5], [27], and it is prudent to emphasize the need for 
serial monitoring of the levels of transaminases over 
time and that the sole monitoring of ALT is not strong 
enough criteria for evaluation of hepatic injury as 
described in the study of Hadziyannis et al.,
 
[7]. 
It is known that maintained high levels of HBV 
DNA are associated with progressive liver disease. 
Serum DNA levels are a prognostic factor, and 
contribute to defining the phases of CHB infection, the 
treatment indication, and allow an assessment of the 
efficacy of antiviral therapy. Kumar et al., [26] in a 
recent, large prospective study have shown clearly 
that baseline ALT, and DNA level is good predictors of 
histologically significant fibrosis. The ten years long 
retrospective study conducted by Madan et al., [28] 
showed that the mean level of HBV DNA is lowest in 
patients' inactive carriers, and it is highest in patients 
with chronic active hepatitis B. Patients inactive 
carriers had significantly lower serum values of HBV 
DNA than patients with HBeAg negative chronic 
hepatitis B. The cut-off values of 3,5 log 10 cp/ml had 
sensitivity and specificity of 83 and 58% respectively 
in differentiation of patient's IC from patients with 
HBeAg negative CHB. The study of Zacharakis et al., 
[29] investigated 263 patients with chronic hepatitis B, 
genotype D, patients who were treatment naïve, 
HBeAg negative, antique positive, and all patients 
inactive carriers had low or almost undetectable levels 
of HBV DNA < 2000 IU/ml, and only 2% had HBV 
DNA reactivation with the level of HBV DNA > 2000 
IU/ml. Similar to these studies, from the patients 
included in our study, patients inactive carriers had 
significantly lower values of serum HBV DNA 
compared to patients with HBeAg-negative CHB. An 
interesting finding in our study was that when the 
levels of HBV DNA were stratified in patients with 
HBeAg-negative CHB, 50.94% had HBV DNA > 2000 
≤ 20 000 IU/ml and 49.06% had HBV DNA > 20 000 
IU/ml. The levels of HBV DNA have to be monitored 
on a close and regular basis in order, not to mistaken 
patients with active hepatitis for inactive carriers, 
especially in patients with HBeAg negative chronic 
hepatitis. In an inactive carrier, ALT usually remains 
normal on serial monitoring with undetectable to low 
levels (i.e., < 2000 IU/ml) of HBV DNA but the same 
can occur in a patient with HBeAg-negative CHB 
[20]. As the understanding of the complex problem 
that HBeAg negative chronic hepatitis B represents 
grows, it is understood that HBV DNA is not always a 
useful indicator for treatment decision. A Chinese 
study, involving 165 patients, reported that a single 
HBV DNA measurement misdiagnosis 45% HBeAg-
negative CHB as chronic inactive HBsAg carriers. The 
study further revealed that even HBV DNA 
measurement on 3 separate occasions also 
misdiagnoses 30% cases [30]. Moreover, a study of 
196 CHB patients revealed that 10.5% HBeAg-
negative CHB patients had HBV DNA < 30,000 
copies/mL [31]. 
Evaluation of the level of quantitative hepatitis 
B surface antigen (qHBsAg) reflects the amount of 
transcriptional activity of cccDNA (covalently closed 
circular DNA) and the integrated DNA in the 
hepatocytes representing one of the main serologic 
markers in chronic HBV infection; accurately 
monitoring both disease progression and prognosis as 
well as response to antiviral therapy [32], [33] At the 
same time, the correlation between the serum levels 
of HBsAg and HBV DNA improves and helps in better 
understanding and following the phases and outcome 
of CHB during its natural history and treatment as well 
[34].
 
 In our cohort, the patients with HBeAg-
negative CHB had significantly higher values of 
qHBsAg compared to patients IC. These findings 
correlate with the studies found in the literature. The 
study of Zhu et al., [35], included 124 patients with 
chronic hepatitis B and demonstrated that there is a 
correlation between HBV DNA and qHBsAg and that 
the serum level of HBsAg reflects the amount of HBV 
DNA replication. The serum levels of HBsAg were 
significantly higher in patients with HBV DNA > 1 х 10
3
 
cp/ml compared to patients with HBV DNA level < 1 х 
10
3
 cp/ml (t = 5.983, p = 0.000 < 0.05). Based on the 
HBV DNA level, the patients were divided into three 
groups: group A (HBV DNA level between 1 х 10
3
 and 
1 х 10
5 
cp/ml, group B (1 х 10
5
 cp/ml till 1 х 10
7
 cp/ml) 
and group C (> 1 х 10
7
 cp/ml). It was shown that the 
level of HBsAg increased with the level of HBV DNA 
and that it was higher in-patient group C Pearson’s 
correlation (r = 0.657, p = 0.000 < 0.05) showed that 
there is a positive correlation between serum HBsAg 
and HBV DNA. 
Dimzova et al. Characteristics of an Outpatient Cohort with HBeAg-Negative Chronic Hepatitis B 
_______________________________________________________________________________________________________________________________ 
_______________________________________________________________________________________________________________________________ 
Open Access Maced J Med Sci. 2019 Jul 15; 7(13):2068-2074.                                                                                                                                                 2073 
 
In many centres which do not have molecular 
biology testing, and in practical terms, ALT levels are 
used to predict the presence of viral replication and 
progression of liver damage. Our study showed that 
the increase of the serum level of HBV DNA is 
followed with a non – significant decrease of ALT both 
in IC and in patients with AH, while the increase of the 
level of quantitative HBsAg is followed with the 
increase of the level of ALT in both groups of patients. 
In our study, the influence of qHBsAg on values of 
ALT was significantly stronger than that of HBV DNA. 
The research done on patients with HBeAg negative 
chronic hepatitis have already demonstrated the weak 
correlation between viral load and transaminases [6]. 
The study of Kim et al., [36] showed that correlation of 
qHBsAg with ALT and HBV DNA can better predict 
the liver (dis)function and that at the same time this 
correlation can be used to discriminate between 
patients' inactive carriers and patients with HBeAg 
negative chronic hepatitis B.  
As it has been said, the assessment of viral 
load is not a sufficient factor for treatment decision, 
and additional factors such as histological factors 
(fibrosis/cirrhosis and liver inflammation), patient age, 
disease evolution over time, family history of HCC, 
have to be taken into account for treatment decision. 
The most recent international guides also point out the 
need for multiple clinical applications, with repeated 
measurements of transaminases and HBV-DNA for 
the determination of the phases of the disease and 
better management of the infected patient [11], [14], 
[15]. 
Our study showed that both groups of 
patients, the inactive carriers and patient with active 
HBeAg negative chronic hepatitis have similar 
laboratory and identical serology profile and that it is 
difficult to determine who to treat based on the level of 
HBV DNA measured at one point of time. The 
presence of a positive correlation between the levels 
of qHBsAg and ALT may suggest the presence of 
more advanced liver disease and active HBV DNA 
replication, which can be taken into consideration for 
treatment decision. An especially interesting group of 
patients in our study are the patients who have normal 
ALT values and HBV DNA level above 2000 IU/ml, but 
less than 20 000 IU/ml, which in our cohort present 
50.94% of patients with chronic HBeAg negative 
hepatitis. The decision of when to start antiviral 
treatment will be the most difficult in this set of 
patients.  
The primary limitations of our study were the 
adoption of the same ALT reference value for male 
and female patients and the absences of the 
histological staging of the liver disease.  
 In conclusion, determination of the phases of 
chronic hepatitis B in patients who are HBeAg 
negative, anti HBeAg positive is of enormous clinical 
importance in order to avoid misclassification of 
patients inactive carriers with patients with HBeAg-
negative CHB since laboratory and virology analysis 
were taken at one point of time can show normal 
transaminase activity and undetectable to low HBV 
DNA viraemia due to the typical intermittent profile of 
HBeAg negative chronic hepatitis B.  
In conformity with literature, the results of our 
study suggest that due to the dynamism of the chronic 
infection by HBV, the infected patient should be 
continuously and carefully evaluated with a joint 
analysis of the clinical, serologic, biochemical, 
molecular biology, and sometimes histologic 
parameters in order to make a timely and proper 
decision when and who to treat. Proper and timely 
initiation of antiviral therapy will prevent the 
development of chronic HBV associated 
complications, and reduce the overall morbidity and 
mortality of these patients.  
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